Using retinal health to assess brain blood vessel conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates whether retinal vasoreactivity can serve as a biomarker for the progression of cerebral small vessel disease (SVD) and evaluates the safety and efficacy of cilostazol, an antiplatelet agent, in slowing SVD progression. Participants will include individuals diagnosed with CADASIL, sporadic white matter disease, and lobar cerebral microbleeding, along with age-matched healthy controls. The study will involve retinal scans, brain imaging, cognitive assessments, and blood samples at baseline and after 12 months. Patients with sporadic white matter disease will be randomized to receive cilostazol or no treatment, with follow-up assessments to monitor disease progression and cognitive changes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 yo.
* Diagnosis of CADASIL, sporadic WMD or lobar CMB and age-matched healthy controls (eg. patient's spouse or unrelated friends without SVD)

Exclusion Criteria:

* Age\<18yo
* Pregnant
* Breast feeding
* Unable to follow commands
* Unable to tolerate MRI

Where it's running

• Mayo Clinic Florida
  Jacksonville, Florida, United States Recruiting

Study contacts

• Principal investigator: Michelle P Lin, MD, MPH — Mayo Clinic
• Study coordinator: Meredith McDonald
• Email: mcdonald.meredith@mayo.edu
• Phone: 904-953-4200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can QSM MRI help tell MS from age-related brain changes in older adults

  This study tests whether an advanced MRI technique called QSM can better differentiate MS-related brain lesions from age-related or small vessel changes in people aged 50–70.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07444047

• Registry for people with cerebral small vessel disease.

  This project will collect clinical information and MRI scans from people aged 50 and older with MRI signs of cerebral small vessel disease to see how the condition relates to thinking, walking, and daily function over time.

  Recruiting Dongzhimen Hospital, Beijing · Beijing, Beijing Municipality · NCT07342075

• Observing brain blood vessel health in a community

  This study looks at how blood vessel health in the brain is affected by conditions like high blood pressure and diabetes in adults aged 50-75 living in Beijing.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT06579677

• Intermittent theta-burst brain stimulation to improve thinking in people with small vessel brain disease

  This trial will try intermittent theta-burst stimulation (a form of noninvasive brain stimulation) to see if it helps cognition in people aged 45–80 with vascular cognitive impairment from cerebral small vessel disease.

  Recruiting Beijing Tiantan Hospital · Beijing · NCT06579664

• Evaluating the effects of Calculus Bovis Sativus for ischemic cerebrovascular diseases

  This study is testing whether a traditional Chinese medicine called Calculus Bovis Sativus can help improve brain health and reduce inflammation in people with ischemic cerebrovascular diseases like stroke.

  Recruiting at 2 sites Tongji Hospital · Wuhan, Hubei and 1 other locations · NCT06474507

• Evaluating retinal health in patients with cerebral small vessel disease

  This study is testing if a special eye scan can help doctors understand how brain health is affected in older adults with cerebral small vessel disease.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT06431711

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.